EXACT Therapeutics completed the dose escalation part of ACTIVATE study

OSLO, 7 August 2023:

EXACT THERAPEUTICS AS today announces that the dose escalation part of the ACTIVATE study is completed.

This part of the study enrolled 8 patients, with 6 patients eligible for evaluation. The study is conducted at the Institute of Cancer Research (ICR), Royal Marsden Hospital, London with Professor Udai Banerji as the principal investigator. A presentation of the safety and efficacy findings will be released when the full results are available.

The study Trial Monitoring Committee reviewed the safety data from the dose escalation and approved initiation of the dose expansion part of the ACTIVATE study. The dose expansion is designed to determine the dose level for further development of ACT and expand the safety and efficacy data with 12 to 20 patients with metastatic colorectal cancer. All necessary approvals have already been awarded by the UK MHRA, as reported on July 31st, and enrolment will now commence.  

For more information, please contact:

Per Walday

CEO EXACT Therapeutics

Email: per.walday@exact-tx.com